Angel Pazos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angel Pazos has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Elena Castro
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) (UC-CSIC-SODERCAN)
6 shared publications - Fuencisla Pilar-Cuéllar
Institute of Biomedicine and Biotechnology of Cantabria, IBBTEC (CSIC, University of Cantabria), Santander, 39011, Spain; Biomedical Research Networking Centre for Mental Health (CIBERSAM), Santander, Spain; Department of Physiology and Pharmacology, Faculty of Medicine, University of Cantabria, Santander, 39011, Spain
6 shared publications - Elsa Maria Valdizán
CIBERSAM, Centro Investigación Biomédica en Red Salud Mental
4 shared publications Rebeca Vidal
3 shared publications- Susana Mato
Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain
3 shared publications - Álvaro Díaz
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) (UC-CSIC-SODERCAN)
3 shared publications
Latest Publications
- Open Access
- 12 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8671
mTOR Knockdown in the Infralimbic Cortex Evokes A Depressive-like State in Mouse
Fast and sustained antidepressant effects of ketamine identified the mammalian target of rapamycin (mTOR) signaling pathway as the main modulator of its antidepressive effects. Thus, mTOR signaling has become integral for the preclinical evaluation of novel compounds to treat depression. However, causality between mTOR and depression has yet to be determined. To address this, we knocked down mTOR expression in mice using an acute intracerebral infusion of small interfering RNAs (siRNA) in the infralimbic (IL) or prelimbic (PrL) cortices of the medial prefrontal cortex (mPFC), and evaluated depressive- and anxious-like behaviors. mTOR knockdown in IL, but not PrL, cortex produced a robust depressive-like phenotype in mice, as assessed in the forced swimming test (FST) and the tail suspension test (TST). This phenotype was associated with significant reductions of mTOR mRNA and protein levels 48 h post-infusion. In parallel, decreased brain-derived neurotrophic factor (BDNF) expression was found bilaterally in both IL and PrL cortices along with a dysregulation of serotonin (5-HT) and glutamate (Glu) release in the dorsal raphe nucleus (DRN). Overall, our results demonstrate causality between mTOR expression in the IL cortex and depressive-like behaviors, but not in anxiety.
- 12 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8671
Open AccessmTOR Knockdown in the Infralimbic Cortex Evokes A Depressive-like State in Mouse
Fast and sustained antidepressant effects of ketamine identified the mammalian target of rapamycin (mTOR) signaling pathway as the main modulator of its antidepressive effects. Thus, mTOR signaling has become integral for the preclinical evaluation of novel compounds to treat depression. However, causality between mTOR and depression has yet to be determined. To address this, we knocked down mTOR expression in mice using an acute intracerebral infusion of small interfering RNAs (siRNA) in the infralimbic (IL) or prelimbic (PrL) cortices of the medial prefrontal cortex (mPFC), and evaluated depressive- and anxious-like behaviors. mTOR knockdown in IL, but not PrL, cortex produced a robust depressive-like phenotype in mice, as assessed in the forced swimming test (FST) and the tail suspension test (TST). This phenotype was associated with significant reductions of mTOR mRNA and protein levels 48 h post-infusion. In parallel, decreased brain-derived neurotrophic factor (BDNF) expression was found bilaterally in both IL and PrL cortices along with a dysregulation of serotonin (5-HT) and glutamate (Glu) release in the dorsal raphe nucleus (DRN). Overall, our results demonstrate causality between mTOR expression in the IL cortex and depressive-like behaviors, but not in anxiety.
- 1 November 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 157, 258-265
Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders
- 1 November 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 157, 258-265
Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders
- 1 June 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (23) , 3751-3762
Serotonin 5-HT4 Receptors: A New Strategy for Developing Fast Acting Antidepressants?
The regulation of the activity of brain monoaminergic systems has been the focus of attention of many studies since the first antidepressant drug emerged 50 years ago. The search for novel antidepressants is deeply linked to the search for fast-acting strategies, taking into account that 2-4 weeks of treatment with classical antidepressant are required before clinical remission of the symptoms becomes evident. In the recent years several hypotheses have been proposed on the basis of the existence of alterations in brain synaptic plasticity in major depression. Recent evidences support a role for 5-HT4 receptors in the pathogenesis of depression as well as in the mechanism of action of antidepressant drugs. In fact, chronic treatment with antidepressant drugs appears to modulate, at different levels, the signaling pathway associated to 5-HT4 receptors, as well as their levels of expression in the brain. Moreover, several experimental studies have identified this receptor subtype as a promising new target for fast-acting antidepressant strategy: the administration of partial agonists of this receptor induces a number of responses similar to those observed after chronic treatment with classical antidepressants, but with a rapid onset of action. They include efficacy in behavioral models of depression, rapid desensitization of 5-HT1A autoreceptors, and modifications in the expression of several molecular markers of brain neuroplasticity. Although much work remains to be done in order to clarify the real therapeutic potential of these drugs, the evidences reviewed below support the hypothesis that 5-HT4 receptor partial agonists could behave as rapid and effective antidepressants.
- 1 June 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (23) , 3751-3762
Serotonin 5-HT4 Receptors: A New Strategy for Developing Fast Acting Antidepressants?
The regulation of the activity of brain monoaminergic systems has been the focus of attention of many studies since the first antidepressant drug emerged 50 years ago. The search for novel antidepressants is deeply linked to the search for fast-acting strategies, taking into account that 2-4 weeks of treatment with classical antidepressant are required before clinical remission of the symptoms becomes evident. In the recent years several hypotheses have been proposed on the basis of the existence of alterations in brain synaptic plasticity in major depression. Recent evidences support a role for 5-HT4 receptors in the pathogenesis of depression as well as in the mechanism of action of antidepressant drugs. In fact, chronic treatment with antidepressant drugs appears to modulate, at different levels, the signaling pathway associated to 5-HT4 receptors, as well as their levels of expression in the brain. Moreover, several experimental studies have identified this receptor subtype as a promising new target for fast-acting antidepressant strategy: the administration of partial agonists of this receptor induces a number of responses similar to those observed after chronic treatment with classical antidepressants, but with a rapid onset of action. They include efficacy in behavioral models of depression, rapid desensitization of 5-HT1A autoreceptors, and modifications in the expression of several molecular markers of brain neuroplasticity. Although much work remains to be done in order to clarify the real therapeutic potential of these drugs, the evidences reviewed below support the hypothesis that 5-HT4 receptor partial agonists could behave as rapid and effective antidepressants.
- 1 June 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (23) , 3717
Editorial (Thematic Issue: Future Trends in the Development of New Antidepressant Drugs)
Editorial.Major depression is a severe psychiatric disorder with very high prevalence and socioeconomic effect. In spite of the intensive research carried out, the biological substrate of this disease is still poorly understood. The monoaminergic theory has been for many years the moststrongly established hypotheses: in line with this, almost all antidepressant drugs currently used act by interacting with monoaminergic neurotransmission.\ud However, these drug present serious limitations, including lack of efficacy and delayed onset of action. Recent data indicate that depression might be also associated with modifications involving cell proliferation and plasticity in some brain limbic areas. These results are leading to the identification of new pharmacological targets for the treatment of depressive disorders. This volume analyzes the most interesting recent findings in this field, suggesting new trends for the development of new and better antidepressants.Peer Reviewe
- 1 June 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (23) , 3717
Editorial (Thematic Issue: Future Trends in the Development of New Antidepressant Drugs)
Editorial.Major depression is a severe psychiatric disorder with very high prevalence and socioeconomic effect. In spite of the intensive research carried out, the biological substrate of this disease is still poorly understood. The monoaminergic theory has been for many years the moststrongly established hypotheses: in line with this, almost all antidepressant drugs currently used act by interacting with monoaminergic neurotransmission.\ud However, these drug present serious limitations, including lack of efficacy and delayed onset of action. Recent data indicate that depression might be also associated with modifications involving cell proliferation and plasticity in some brain limbic areas. These results are leading to the identification of new pharmacological targets for the treatment of depressive disorders. This volume analyzes the most interesting recent findings in this field, suggesting new trends for the development of new and better antidepressants.Peer Reviewe
- Open Access
- 2 June 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (05) , 631-643
Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333
It has been recently suggested that activation of 5-HT4 receptors might exert antidepressant-like effects in rats after 3 d treatment, suggesting a ne
- 2 June 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (05) , 631-643
Open AccessModulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333
It has been recently suggested that activation of 5-HT4 receptors might exert antidepressant-like effects in rats after 3 d treatment, suggesting a ne
- Open Access
- 31 May 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (4b) , 1046-1057
Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain‐derived neurotrophic factor, β‐catenin and antidepressant‐like effects
BACKGROUND AND PURPOSE: 5‐HT2A receptor antagonists improve antidepressant responses when added to 5‐HT‐selective reuptake inhibitors (SSRIs) or tricyclic antidepressants. Here, we have studied the involvement of neuroplasticity pathways and/or the 5‐hydroxytryptaminergic system in the antidepressant‐like effect of this combined treatment, given subchronically.EXPERIMENTAL APPROACH: Expression of brain‐derived neurotrophic factor (BDNF) and its receptor (TrkB), 5‐bromo‐2′‐deoxyuridine (BrdU) incorporation, and β‐catenin protein expression in different cellular fractions, as well as 5‐HT1A receptor function were measured in the hippocampus of rats treated with fluoxetine, ketanserin and fluoxetine + ketanserin for 7 days, followed by a forced swimming test (FST) to analyse antidepressant efficacy.KEY RESULTS: mRNA for BDNF was increased in the CA3 field and dentate gyrus of the hippocampus by combined treatment with fluoxetine + ketanserin. Expression of β‐catenin was increased in total hippocampal homogenate and in the membrane fraction, but unchanged in the nuclear fraction after combined treatment with fluoxetine + ketanserin. These effects were paralleled by a decreased immobility time in the FST. There were no changes in BrdU incorporation, TrkB expression and 5‐HT1A receptor function in any of the groups studied.CONCLUSIONS AND IMPLICATIONS: The antidepressant‐like effect induced by subchronic co‐treatment with a SSRI and a 5‐HT2A receptor antagonist may mainly be because of modifications in hippocampal neuroplasticity (BDNF and membrane‐associated β‐catenin), without a significant role for other mechanisms involved in chronic antidepressant response, such as hippocampal neuroproliferation or 5‐HT1A receptor desensitization in the dorsal raphe nucleus.
- 31 May 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (4b) , 1046-1057
Open AccessSubchronic treatment with fluoxetine and ketanserin increases hippocampal brain‐derived neurotrophic factor, β‐catenin and antidepressant‐like effects
BACKGROUND AND PURPOSE: 5‐HT2A receptor antagonists improve antidepressant responses when added to 5‐HT‐selective reuptake inhibitors (SSRIs) or tricyclic antidepressants. Here, we have studied the involvement of neuroplasticity pathways and/or the 5‐hydroxytryptaminergic system in the antidepressant‐like effect of this combined treatment, given subchronically.EXPERIMENTAL APPROACH: Expression of brain‐derived neurotrophic factor (BDNF) and its receptor (TrkB), 5‐bromo‐2′‐deoxyuridine (BrdU) incorporation, and β‐catenin protein expression in different cellular fractions, as well as 5‐HT1A receptor function were measured in the hippocampus of rats treated with fluoxetine, ketanserin and fluoxetine + ketanserin for 7 days, followed by a forced swimming test (FST) to analyse antidepressant efficacy.KEY RESULTS: mRNA for BDNF was increased in the CA3 field and dentate gyrus of the hippocampus by combined treatment with fluoxetine + ketanserin. Expression of β‐catenin was increased in total hippocampal homogenate and in the membrane fraction, but unchanged in the nuclear fraction after combined treatment with fluoxetine + ketanserin. These effects were paralleled by a decreased immobility time in the FST. There were no changes in BrdU incorporation, TrkB expression and 5‐HT1A receptor function in any of the groups studied.CONCLUSIONS AND IMPLICATIONS: The antidepressant‐like effect induced by subchronic co‐treatment with a SSRI and a 5‐HT2A receptor antagonist may mainly be because of modifications in hippocampal neuroplasticity (BDNF and membrane‐associated β‐catenin), without a significant role for other mechanisms involved in chronic antidepressant response, such as hippocampal neuroproliferation or 5‐HT1A receptor desensitization in the dorsal raphe nucleus.
- 15 January 2011
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 35 (1) , 84-90
Straight gyrus morphology in first-episode schizophrenia-spectrum patients
- 15 January 2011
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 35 (1) , 84-90
Straight gyrus morphology in first-episode schizophrenia-spectrum patients
- 30 December 2010
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 184 (3) , 189-191
Temporal pole morphology in first-episode schizophrenia patients:: Clinical correlations
- 30 December 2010
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 184 (3) , 189-191
Temporal pole morphology in first-episode schizophrenia patients:: Clinical correlations
- 1 November 2010
- Published by Elsevier in Biological Psychiatry
- Vol. 68 (9) , 869-872
α2-Adrenoceptor Functionality in Postmortem Frontal Cortex of Depressed Suicide Victims
- 1 November 2010
- Published by Elsevier in Biological Psychiatry
- Vol. 68 (9) , 869-872
α2-Adrenoceptor Functionality in Postmortem Frontal Cortex of Depressed Suicide Victims
- 13 July 2009
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (3) , 1120-1127
Long‐term treatment with fluoxetine induces desensitization of 5‐HT4receptor‐dependent signalling and functionality in rat brain
The mode of action of antidepressant drugs may be related to mechanisms of monoamines receptor adaptation, including serotonin 5‐HT4receptor subtypes. Here we investigated the effects of repeated treatment with the selective serotonin reuptake inhibitor fluoxetine for 21 days (5 and 10 mg/kg, p.o., once daily) on the sensitivity of 5‐HT4receptors by using receptor autoradiography, adenylate cyclase assays and extracellular recording techniques in rat brain. Fluoxetine treatment decreased the density of 5‐HT4receptor binding in the CA1 field of hippocampus as well as in several areas of the striatum over the doses of 5–10 mg/kg. In a similar way, we found a significant lower response to zacopride‐stimulated adenylate cyclase activity in the fluoxetine 10 mg/kg/day treated group. Furthermore, post‐synaptic 5‐HT4receptor activity in hippocampus‐measured as the excitatory action of zacopride in the pyramidal cells of CA1 evoked by Schaffer collateral stimulation was attenuated in rats treated with both doses of fluoxetine. Taken together, these results support the concept that a net decrease in the signalization pathway of 5‐HT4receptors occurs after chronic selective serotonin reuptake inhibitor treatment: this effect may underlie the therapeutic efficacy of these drugs.
- 13 July 2009
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (3) , 1120-1127
Long‐term treatment with fluoxetine induces desensitization of 5‐HT4receptor‐dependent signalling and functionality in rat brain
The mode of action of antidepressant drugs may be related to mechanisms of monoamines receptor adaptation, including serotonin 5‐HT4receptor subtypes. Here we investigated the effects of repeated treatment with the selective serotonin reuptake inhibitor fluoxetine for 21 days (5 and 10 mg/kg, p.o., once daily) on the sensitivity of 5‐HT4receptors by using receptor autoradiography, adenylate cyclase assays and extracellular recording techniques in rat brain. Fluoxetine treatment decreased the density of 5‐HT4receptor binding in the CA1 field of hippocampus as well as in several areas of the striatum over the doses of 5–10 mg/kg. In a similar way, we found a significant lower response to zacopride‐stimulated adenylate cyclase activity in the fluoxetine 10 mg/kg/day treated group. Furthermore, post‐synaptic 5‐HT4receptor activity in hippocampus‐measured as the excitatory action of zacopride in the pyramidal cells of CA1 evoked by Schaffer collateral stimulation was attenuated in rats treated with both doses of fluoxetine. Taken together, these results support the concept that a net decrease in the signalization pathway of 5‐HT4receptors occurs after chronic selective serotonin reuptake inhibitor treatment: this effect may underlie the therapeutic efficacy of these drugs.